Abstract:Antibody-drug conjugates (ADCs) are a class of antineoplastic agents whose structure is composed of three main components: a monoclonal antibody (mAB) targeting a specific target antigen, a cytotoxic payload, and a linker binding the antibody to the payload. By combining the specificity of mABs with the high potency of the payloads, ADCs constitute a smart drug delivery system with improved therapeutic index. After recognition and binding of the mAB to its target surface antigen, ADCs are internalized by endocytosis by the tumor cell, releasing the payloads into the cytoplasm, where they exert their cytotoxic activity, eventually leading to cell death. The composition of some of the new ADCs confers additional functional properties that allow expanding their activity to neighboring cells not expressing the target antigen, constituting a valuable strategy to overcome tumor heterogeneity. Some of these 'off-target effects', such as the bystander effect, are possibly the mechanism underlying the antitumor activity demonstrated in patients with low expression of the target antigens, which represents an important paradigm shift in anticancer targeted therapy. Three ADCs are currently approved for the treatment of breast cancer (BC); two anti-HER2 (human epidermal growth factor receptor 2) ADCs (trastuzumab emtansine and trastuzumab deruxtecan); and one Trop-2-targeted ADC (sacituzumab govitecan). Based on the unprecedented efficacy data demonstrated by these agents, ADCs have been incorporated as part of standard regimens for all subtypes of advanced BC, as well as for high-risk early HER2-positive BC. Despite the remarkable advances, several hurdles still remain to overcome, including the development of reliable biomarkers for patient selection, prevention, and management of potentially severe toxicities, ADC resistance mechanisms, post-ADC resistance patterns, and optimal treatment sequencing and combinations. In this review, we will summarize the currently available evidence related to the use of these agents, as well as explore the current landscape of ADC development for BC treatment.

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors

Antibody-Drug Conjugates in Gynecologic Cancers

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer

Antibody-drug conjugates in gynecologic malignancies

Antibody-Drug Conjugates in Gynecologic Cancer

Advances in antibody-drug conjugates for gynecologic malignancies

The target invites a foe: antibody-drug conjugates in gynecologic oncology

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

[Antibody-Drug Conjugates in Breast Cancer and Gynecologic Cancer]

A Narrative Review of Human Epidermal Growth Factor Receptor 2 (Her2)-Targeted Antibody-Drug Conjugates in the Treatment of Breast Cancer

The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases

Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions

Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2

A Review of Current and Future Antibody Drug Conjugates in Breast Cancer

Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis

Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment

The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads

[Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression]

Breast Cancer Treatment and Antibody Drug Conjugates: Beyond T-DM1

Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions